User: prashantiyengar Topic: IP
Category: drugs :: india
Last updated: Jul 21 2018 12:00 IST RSS 2.0
 
1 to 20 of 2,822    
'This movie has made China introspect and learn from India' 21.7.2018 Rediff: Columns
Dying To Survive, on its way to becoming China's biggest box office hit, may compel the Xi Jinping government to change its policy towards Indian pharmaceutical companies, says Tarun Vijay.
Also found in: [+]
Will this movie change China's drug policy towards India? 14.7.2018 Rediff: News
Dying To Survive, on its way to becoming China's biggest box office hit, may compel the Xi Jinping government to change its policy towards Indian pharmaceutical companies, says Tarun Vijay.
Also found in: [+]
CSIR bags the Clarivate Analytics India Innovation Award 2018 in the Government Research Organizations Category 24.5.2018 Govt of india: PIB
Council of Scientific & Industrial Research has been awarded the Clarivate Analytics India Innovation Award 2018 in the Government Research Organizations Category. This award yet again recognizes CSIR as the top innovator.
Also found in: [+]
Ayushman Bharat may help patients access life-saving drugs 16.5.2018 Rediff: Top Stories (India)
'We have often heard the mythical argument that patents block access to life-saving drugs, but only 5% of medicines from multinational companies are under patent protection in India.''Where these patented products are beyond the reach of Indian patients, the companies have programmes to facilitate access to their drugs, for free or for a fraction of the price,' points out Ranjana Smetacek, former director general, Organisation of Pharmaceutical Producers of India.
Also found in: [+]
Prices of key diabetes, cancer drugs may drop by 25% 8.3.2018 Rediff: Business
A recent report has suggested that future patent expires in the cardiac and anti-diabetes space would form a good opportunity for smaller firms, given their franchise in these segments.
Also found in: [+]
Indian pharma growth likely to be moderate: ICRA 3.1.2018 Sify Finance
[India], Jan 3 (ANI): The growth trajectory for Indian pharmaceutical industry is likely to be moderate, according to credit rating agency ICRA.
Also found in: [+]
Morepen Gets US FDA clearance for its Bulk Drug Montelukast Sodium 20.12.2017 Sify Finance
[India], Dec 20 (ANI-NewsVoir): The United States Food and Drug Administration (USFDA) has cleared Montelukast Sodium, a bulk drug / API manufactured by Morepen Laboratories Ltd., for sale in the
Also found in: [+]
BRIEF-India's Lincoln Pharmaceuticals Gets Patent For 'Antimalarial Drug' 19.12.2017 Sify Finance
Dec 19 (Reuters) - Lincoln Pharmaceuticals Ltd:
Also found in: [+]
After 15 years, Ranjit Shahani steps down as Novartis MD 14.11.2017 Rediff: Business
The face of MNC drug firms in India and champion of IPR protection, he oversaw the Swiss giant's India expansion, its forays into new therapies and setting up of its global service centre in Hyderabad
Also found in: [+]
Base Erosion and Profit Shifting guidelines stump MNCs 14.10.2017 ET: Pharma
Under BEPS, multinationals will be required to declare details of revenues earned, taxes paid, employees hired, supply chain management in every country they operate in.
Also found in: [+]
Activists challenge Pneumonia vaccine patent in Delhi High Court 14.10.2017 DNA: Mumbai
Activists have challenged the patent claims of pharma giant Pfizer on a vaccine for pneumonia in the Delhi High Court. Médecins Sans Frontières or Doctors Without Borders (India) has filed a petition to overturn the patent granted earlier this year, on August 13 by the Indian Patent Office to Pfizer. “India has dashed hopes for improved access to an affordable PCV13 when it granted a patent to Pfizer for its PCV 13 product, marketed as Prevnar13, which will expire only in 2026,” a statement issued by MSF said. In the petition, MSF argues that in August 2017, the Delhi Patent Office erroneously granted a patent to Pfizer by disregarding the evidence MSF produced indicating that the pharmaceutical giant’s claim to a patent was spurious. MSF argued that the mere addition of serotypes to the already established 7-valent vaccine did not involve a technical advancement – it was merely a tactic to preserve Pfizer’s monopoly for many more years. The decision also has broader implications, as it indicates a ...
Also found in: [+]
MSF drags govt to Delhi HC over Pfizer's pneumonia vaccine patent 14.10.2017 ET: Pharma
The Indian patent office granted Pfizer a patent for its vaccine PCV13 (13-valent pneumococcal conjugate vaccine), sold here under the brand ‘Prevenar13’ for over 10 years.
Also found in: [+]
U.S. STOCKS ON THE MOVE-Oracle, Genworth, Airlines, Carnival Corp, Mirati Therapeutics 15.9.2017 TOI: Intl Business
MARKETS-USA-STOCKS/PULSE:BUZZ-U.S. STOCKS ON THE MOVE-Oracle, Genworth, Airlines, Carnival Corp, Mirati Therapeutics
Also found in: [+]
Challenge of Allergan tribal patent deal in uncharted legal territory 15.9.2017 TOI: Intl Business
ALLERGAN-PATENTS/ (CORRECTED):REFILE-Challenge of Allergan tribal patent deal in uncharted legal territory
Also found in: [+]
Pharma companies inflating R&D costs? 14.9.2017 TOI: India
Also found in: [+]
Mylan says Allergan misusing tribal sovereignty in patent dispute 13.9.2017 TOI: Intl Business
ALLERGAN-PATENTS/MYLAN:Mylan says Allergan misusing tribal sovereignty in patent dispute
Also found in: [+]
U.S. tribal patent deal could have big impact on generic drug market 12.9.2017 TOI: Intl Business
ALLERGAN-PATENTS/MOHAWK:U.S. tribal patent deal could have big impact on generic drug market
Also found in: [+]
Modi govt developed Brand India: Amit Shah 10.9.2017 DNA: Mumbai
In his first address to India Inc at the Federation of Indian Chambers of Commerce and Industry's national executive meet, BJP chief Amit Shah on Saturday described various measures taken by Modi government, like GST and demonetization, as an effort to implement policies aimed at long-term gains. "We are looking to provide a stable policy for 30 years," said Shah adding that GST will reap benefits in the next 10 years. He said the biggest achievement of Modi government has been bringing forth a paradigm shift in the scale of thinking. "An image of Brand India has developed because of PM Modi's government." He asked organisations like FICCI to constitute consortium for research and development, especially in sectors like pharmaceuticals, so the country can make a profit from patent registration and intellectual property rights. Shah lambasted the UPA government for its 10-year rule riddled with scams and blamed it on the accumulated NPAs (non-performing assets). "The country was engulfed in an atmosphere ...
Also found in: [+]
London-listed drugmaker Indivior shares crash after U.S. patent blow 1.9.2017 TOI: Intl Business
INDIVIOR-RULING:London-listed drugmaker Indivior shares crash after U.S. patent blow
Also found in: [+]
UPDATE 1-London-listed drugs firm Indivior suffers setback in U.S. patents ruling 1.9.2017 TOI: Intl Business
INDIVIOR-RULING/ (CORRECTED, UPDATE 1):REFILE-UPDATE 1-London-listed drugs firm Indivior suffers setback in U.S. patents ruling
Also found in: [+]
1 to 20 of 2,822